JP2015529194A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015529194A5 JP2015529194A5 JP2015527558A JP2015527558A JP2015529194A5 JP 2015529194 A5 JP2015529194 A5 JP 2015529194A5 JP 2015527558 A JP2015527558 A JP 2015527558A JP 2015527558 A JP2015527558 A JP 2015527558A JP 2015529194 A5 JP2015529194 A5 JP 2015529194A5
- Authority
- JP
- Japan
- Prior art keywords
- substituted
- unsubstituted
- group
- alkyl
- methyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 125000000217 alkyl group Chemical group 0.000 claims 20
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 17
- 230000002062 proliferating effect Effects 0.000 claims 17
- 201000010099 disease Diseases 0.000 claims 13
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 12
- 229910052739 hydrogen Inorganic materials 0.000 claims 12
- 239000001257 hydrogen Substances 0.000 claims 12
- 125000001424 substituent group Chemical group 0.000 claims 12
- 229910052736 halogen Inorganic materials 0.000 claims 10
- 206010039491 Sarcoma Diseases 0.000 claims 9
- 125000003545 alkoxy group Chemical group 0.000 claims 9
- 201000011510 cancer Diseases 0.000 claims 9
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims 8
- 206010028980 Neoplasm Diseases 0.000 claims 8
- 229910052805 deuterium Inorganic materials 0.000 claims 8
- 239000008194 pharmaceutical composition Substances 0.000 claims 8
- 125000004093 cyano group Chemical group *C#N 0.000 claims 7
- 125000001153 fluoro group Chemical group F* 0.000 claims 7
- 150000002367 halogens Chemical class 0.000 claims 7
- 150000003839 salts Chemical class 0.000 claims 6
- 150000001875 compounds Chemical class 0.000 claims 5
- 125000000753 cycloalkyl group Chemical group 0.000 claims 5
- 125000001072 heteroaryl group Chemical group 0.000 claims 5
- 125000003118 aryl group Chemical group 0.000 claims 4
- -1 cyano, imidazolyl Chemical group 0.000 claims 4
- 208000035475 disorder Diseases 0.000 claims 4
- 208000005017 glioblastoma Diseases 0.000 claims 4
- 125000005843 halogen group Chemical group 0.000 claims 4
- 125000000623 heterocyclic group Chemical group 0.000 claims 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 4
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 3
- 208000009746 Adult T-Cell Leukemia-Lymphoma Diseases 0.000 claims 3
- 208000016683 Adult T-cell leukemia/lymphoma Diseases 0.000 claims 3
- 206010003571 Astrocytoma Diseases 0.000 claims 3
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 3
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 3
- 206010025323 Lymphomas Diseases 0.000 claims 3
- 206010027406 Mesothelioma Diseases 0.000 claims 3
- 208000034578 Multiple myelomas Diseases 0.000 claims 3
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 3
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 3
- CXQHYVUVSFXTMY-UHFFFAOYSA-N N1'-[3-fluoro-4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinolinyl]oxy]phenyl]-N1-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide Chemical compound C1=CN=C2C=C(OCCCN3CCOCC3)C(OC)=CC2=C1OC(C(=C1)F)=CC=C1NC(=O)C1(C(=O)NC=2C=CC(F)=CC=2)CC1 CXQHYVUVSFXTMY-UHFFFAOYSA-N 0.000 claims 3
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 3
- 102000008022 Proto-Oncogene Proteins c-met Human genes 0.000 claims 3
- 108010089836 Proto-Oncogene Proteins c-met Proteins 0.000 claims 3
- 208000021712 Soft tissue sarcoma Diseases 0.000 claims 3
- 208000008383 Wilms tumor Diseases 0.000 claims 3
- 201000006966 adult T-cell leukemia Diseases 0.000 claims 3
- 210000000481 breast Anatomy 0.000 claims 3
- 210000003679 cervix uteri Anatomy 0.000 claims 3
- 125000001309 chloro group Chemical group Cl* 0.000 claims 3
- 208000006990 cholangiocarcinoma Diseases 0.000 claims 3
- 230000001419 dependent effect Effects 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 210000004696 endometrium Anatomy 0.000 claims 3
- 210000003238 esophagus Anatomy 0.000 claims 3
- 210000003128 head Anatomy 0.000 claims 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 3
- 210000003734 kidney Anatomy 0.000 claims 3
- 210000004185 liver Anatomy 0.000 claims 3
- 210000004072 lung Anatomy 0.000 claims 3
- 201000001441 melanoma Diseases 0.000 claims 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 3
- 210000001989 nasopharynx Anatomy 0.000 claims 3
- 210000003739 neck Anatomy 0.000 claims 3
- 201000008026 nephroblastoma Diseases 0.000 claims 3
- 125000000449 nitro group Chemical class [O-][N+](*)=O 0.000 claims 3
- 210000001672 ovary Anatomy 0.000 claims 3
- 210000000496 pancreas Anatomy 0.000 claims 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 3
- 239000002935 phosphatidylinositol 3 kinase inhibitor Substances 0.000 claims 3
- 229940043441 phosphoinositide 3-kinase inhibitor Drugs 0.000 claims 3
- 210000002307 prostate Anatomy 0.000 claims 3
- 210000002784 stomach Anatomy 0.000 claims 3
- 210000001685 thyroid gland Anatomy 0.000 claims 3
- 210000003932 urinary bladder Anatomy 0.000 claims 3
- OAWXZFGKDDFTGS-BYPYZUCNSA-N (2s)-pyrrolidine-1,2-dicarboxylic acid Chemical compound OC(=O)[C@@H]1CCCN1C(O)=O OAWXZFGKDDFTGS-BYPYZUCNSA-N 0.000 claims 2
- CWHUFRVAEUJCEF-UHFFFAOYSA-N BKM120 Chemical compound C1=NC(N)=CC(C(F)(F)F)=C1C1=CC(N2CCOCC2)=NC(N2CCOCC2)=N1 CWHUFRVAEUJCEF-UHFFFAOYSA-N 0.000 claims 2
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 claims 2
- 125000003342 alkenyl group Chemical group 0.000 claims 2
- 125000003282 alkyl amino group Chemical group 0.000 claims 2
- 125000000304 alkynyl group Chemical group 0.000 claims 2
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 2
- 201000007450 intrahepatic cholangiocarcinoma Diseases 0.000 claims 2
- LVTJOONKWUXEFR-FZRMHRINSA-N protoneodioscin Natural products O(C[C@@H](CC[C@]1(O)[C@H](C)[C@@H]2[C@]3(C)[C@H]([C@H]4[C@@H]([C@]5(C)C(=CC4)C[C@@H](O[C@@H]4[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@@H](O)[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@H](CO)O4)CC5)CC3)C[C@@H]2O1)C)[C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](CO)O1 LVTJOONKWUXEFR-FZRMHRINSA-N 0.000 claims 2
- 229940124617 receptor tyrosine kinase inhibitor Drugs 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- 125000001425 triazolyl group Chemical group 0.000 claims 2
- GLBZSOQDAOLMGC-UHFFFAOYSA-N 1-(2-hydroxy-2-methylpropyl)-n-[5-(7-methoxyquinolin-4-yl)oxypyridin-2-yl]-5-methyl-3-oxo-2-phenylpyrazole-4-carboxamide Chemical compound C=1C=NC2=CC(OC)=CC=C2C=1OC(C=N1)=CC=C1NC(=O)C(C1=O)=C(C)N(CC(C)(C)O)N1C1=CC=CC=C1 GLBZSOQDAOLMGC-UHFFFAOYSA-N 0.000 claims 1
- 229940126062 Compound A Drugs 0.000 claims 1
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 claims 1
- 239000002146 L01XE16 - Crizotinib Substances 0.000 claims 1
- UCEQXRCJXIVODC-PMACEKPBSA-N LSM-1131 Chemical compound C1CCC2=CC=CC3=C2N1C=C3[C@@H]1C(=O)NC(=O)[C@H]1C1=CNC2=CC=CC=C12 UCEQXRCJXIVODC-PMACEKPBSA-N 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010027476 Metastases Diseases 0.000 claims 1
- 229940127361 Receptor Tyrosine Kinase Inhibitors Drugs 0.000 claims 1
- 125000004457 alkyl amino carbonyl group Chemical group 0.000 claims 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims 1
- 150000001412 amines Chemical class 0.000 claims 1
- 125000003277 amino group Chemical group 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- KTEIFNKAUNYNJU-GFCCVEGCSA-N crizotinib Chemical compound O([C@H](C)C=1C(=C(F)C=CC=1Cl)Cl)C(C(=NC=1)N)=CC=1C(=C1)C=NN1C1CCNCC1 KTEIFNKAUNYNJU-GFCCVEGCSA-N 0.000 claims 1
- 229960005061 crizotinib Drugs 0.000 claims 1
- JOGKUKXHTYWRGZ-UHFFFAOYSA-N dactolisib Chemical group O=C1N(C)C2=CN=C3C=CC(C=4C=C5C=CC=CC5=NC=4)=CC3=C2N1C1=CC=C(C(C)(C)C#N)C=C1 JOGKUKXHTYWRGZ-UHFFFAOYSA-N 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 229950008692 foretinib Drugs 0.000 claims 1
- 125000002883 imidazolyl group Chemical group 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 208000014899 intrahepatic bile duct cancer Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 125000001624 naphthyl group Chemical group 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- 125000004043 oxo group Chemical group O=* 0.000 claims 1
- 125000005476 oxopyrrolidinyl group Chemical group 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 claims 1
- 125000004193 piperazinyl group Chemical group 0.000 claims 1
- 125000003226 pyrazolyl group Chemical group 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 1
- 125000002112 pyrrolidino group Chemical group [*]N1C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 claims 1
- 150000003254 radicals Chemical class 0.000 claims 1
- 229940124530 sulfonamide Drugs 0.000 claims 1
- 150000003456 sulfonamides Chemical class 0.000 claims 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261683790P | 2012-08-16 | 2012-08-16 | |
| US61/683,790 | 2012-08-16 | ||
| PCT/US2013/054848 WO2014028566A1 (en) | 2012-08-16 | 2013-08-14 | Combination of pi3k inhibitor and c-met inhibitor |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017201774A Division JP6644042B2 (ja) | 2012-08-16 | 2017-10-18 | ＰＩ３Ｋインヒビターとｃ−Ｍｅｔインヒビターの組み合わせ |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015529194A JP2015529194A (ja) | 2015-10-05 |
| JP2015529194A5 true JP2015529194A5 (enExample) | 2016-09-29 |
Family
ID=49004065
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015527558A Withdrawn JP2015529194A (ja) | 2012-08-16 | 2013-08-14 | ＰＩ３Ｋインヒビターとｃ−Ｍｅｔインヒビターの組み合わせ |
| JP2017201774A Expired - Fee Related JP6644042B2 (ja) | 2012-08-16 | 2017-10-18 | ＰＩ３Ｋインヒビターとｃ−Ｍｅｔインヒビターの組み合わせ |
| JP2020000928A Expired - Fee Related JP6970217B2 (ja) | 2012-08-16 | 2020-01-07 | ＰＩ３Ｋインヒビターとｃ−Ｍｅｔインヒビターの組み合わせ |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017201774A Expired - Fee Related JP6644042B2 (ja) | 2012-08-16 | 2017-10-18 | ＰＩ３Ｋインヒビターとｃ−Ｍｅｔインヒビターの組み合わせ |
| JP2020000928A Expired - Fee Related JP6970217B2 (ja) | 2012-08-16 | 2020-01-07 | ＰＩ３Ｋインヒビターとｃ−Ｍｅｔインヒビターの組み合わせ |
Country Status (14)
| Country | Link |
|---|---|
| US (5) | US20150216870A1 (enExample) |
| EP (1) | EP2885003B1 (enExample) |
| JP (3) | JP2015529194A (enExample) |
| KR (2) | KR102245985B1 (enExample) |
| CN (1) | CN105050623B (enExample) |
| AU (4) | AU2013302702A1 (enExample) |
| BR (1) | BR112015002528A2 (enExample) |
| CA (1) | CA2879704A1 (enExample) |
| ES (1) | ES2901712T3 (enExample) |
| HK (1) | HK1211476A1 (enExample) |
| IN (1) | IN2015DN00528A (enExample) |
| MX (1) | MX369518B (enExample) |
| RU (1) | RU2705095C2 (enExample) |
| WO (1) | WO2014028566A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6026544B2 (ja) | 2011-09-27 | 2016-11-16 | ノバルティス アーゲー | 変異体ｉｄｈの阻害剤としての３−ピリミジン−４−イル−オキサゾリジン−２−オン類 |
| UY34632A (es) | 2012-02-24 | 2013-05-31 | Novartis Ag | Compuestos de oxazolidin- 2- ona y usos de los mismos |
| EP3964513A1 (en) | 2012-04-03 | 2022-03-09 | Novartis AG | Combination products with tyrosine kinase inhibitors and their use |
| US9296733B2 (en) | 2012-11-12 | 2016-03-29 | Novartis Ag | Oxazolidin-2-one-pyrimidine derivative and use thereof for the treatment of conditions, diseases and disorders dependent upon PI3 kinases |
| WO2014141104A1 (en) | 2013-03-14 | 2014-09-18 | Novartis Ag | 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh |
| EP3010505A1 (en) * | 2013-06-18 | 2016-04-27 | Novartis AG | Pharmaceutical combinations |
| JP2016531907A (ja) | 2013-08-02 | 2016-10-13 | アデュロ・バイオテック・ホールディングス・ヨーロッパ・ベスローテン・フエンノートシャップＡｄｕｒｏ Ｂｉｏｔｅｃｈ Ｈｏｌｄｉｎｇｓ， Ｅｕｒｏｐｅ Ｂ．Ｖ． | 免疫刺激のためのｃｄ２７アゴニストと免疫チェックポイント阻害との組み合わせ |
| EA039220B1 (ru) | 2014-07-25 | 2021-12-20 | Новартис Аг | СОСТАВ ТАБЛЕТКИ 2-ФТОР-N-МЕТИЛ-4-[7-(ХИНОЛИН-6-ИЛМЕТИЛ)ИМИДАЗО[1,2-b][1,2,4]ТРИАЗИН-2-ИЛ]БЕНЗАМИДА |
| CN108367003B (zh) | 2014-12-12 | 2022-01-21 | 麻省总医院 | 乳腺癌脑转移的治疗 |
| GB201516504D0 (en) | 2015-09-17 | 2015-11-04 | Astrazeneca Ab | Imadazo(4,5-c)quinolin-2-one Compounds and their use in treating cancer |
| MX2022007625A (es) * | 2019-12-20 | 2022-08-16 | Recurium Ip Holdings Llc | Combinaciones. |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0211649D0 (en) * | 2002-05-21 | 2002-07-03 | Novartis Ag | Organic compounds |
| GB0510390D0 (en) * | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
| JO2660B1 (en) * | 2006-01-20 | 2012-06-17 | نوفارتيس ايه جي | Pi-3 inhibitors and methods of use |
| MY188335A (en) * | 2006-11-22 | 2021-11-30 | Incyte Holdings Corp | Imidazotriazines and imidazopyrimidines as kinase inhibitors |
| WO2008103636A1 (en) * | 2007-02-20 | 2008-08-28 | Novartis Ag | Imidazoquinolines as dual lipid kinase and mtor inhibitors |
| JP2011513364A (ja) * | 2008-03-05 | 2011-04-28 | ノバルティス アーゲー | Ｅｇｆｒ依存性疾患またはｅｇｆｒファミリーメンバーを標的とする薬剤に対して耐性を獲得した疾患を治療するためのピリミジン誘導体の使用 |
| BRPI0912882A2 (pt) * | 2008-05-21 | 2017-05-16 | Incyte Corp | sais de 2-flúor-n-metil-4-[7-(quinolin-6-il-metil)-imidazo[1,2-b][1,2,4]triazin-2-il]benzamida e processos relacionados à preparação dos mesmos |
| CN102089007B (zh) * | 2008-07-11 | 2013-05-15 | 诺瓦提斯公司 | (a)磷酸肌醇3-激酶抑制剂和(b)ras/raf/mek通路调节剂的组合产品 |
| UA104147C2 (uk) * | 2008-09-10 | 2014-01-10 | Новартис Аг | Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань |
| US20100267742A1 (en) * | 2009-04-17 | 2010-10-21 | Rush University Medical Center | Combination targeted therapy for lung cancer |
| AR083267A1 (es) * | 2010-10-04 | 2013-02-13 | Novartis Ag | Combinaciones farmaceuticas |
| MX360157B (es) | 2010-11-08 | 2018-10-24 | Novartis Ag | Uso de derivados de 2-carboxamida-cicloamino-urea en el tratamiento de enfermedades dependientes de egfr o de enfermedades que han adquirido resistencia a los agentes que tienen como objetivo los miembros de la familia egfr. |
-
2013
- 2013-08-14 RU RU2015108755A patent/RU2705095C2/ru active
- 2013-08-14 US US14/420,792 patent/US20150216870A1/en not_active Abandoned
- 2013-08-14 CN CN201380043882.3A patent/CN105050623B/zh not_active Expired - Fee Related
- 2013-08-14 ES ES13751058T patent/ES2901712T3/es active Active
- 2013-08-14 JP JP2015527558A patent/JP2015529194A/ja not_active Withdrawn
- 2013-08-14 HK HK15112283.4A patent/HK1211476A1/xx unknown
- 2013-08-14 WO PCT/US2013/054848 patent/WO2014028566A1/en not_active Ceased
- 2013-08-14 IN IN528DEN2015 patent/IN2015DN00528A/en unknown
- 2013-08-14 BR BR112015002528-5A patent/BR112015002528A2/pt not_active Application Discontinuation
- 2013-08-14 EP EP13751058.2A patent/EP2885003B1/en not_active Not-in-force
- 2013-08-14 CA CA2879704A patent/CA2879704A1/en not_active Abandoned
- 2013-08-14 KR KR1020157003716A patent/KR102245985B1/ko not_active Expired - Fee Related
- 2013-08-14 MX MX2015002005A patent/MX369518B/es active IP Right Grant
- 2013-08-14 KR KR1020217012172A patent/KR20210049187A/ko not_active Ceased
- 2013-08-14 AU AU2013302702A patent/AU2013302702A1/en not_active Abandoned
-
2016
- 2016-10-06 AU AU2016238903A patent/AU2016238903A1/en not_active Abandoned
-
2017
- 2017-10-18 JP JP2017201774A patent/JP6644042B2/ja not_active Expired - Fee Related
-
2018
- 2018-03-09 AU AU2018201725A patent/AU2018201725A1/en not_active Abandoned
- 2018-10-11 US US16/157,333 patent/US20190083500A1/en not_active Abandoned
-
2019
- 2019-07-30 US US16/526,027 patent/US20190350935A1/en not_active Abandoned
- 2019-09-05 AU AU2019226212A patent/AU2019226212B2/en not_active Ceased
-
2020
- 2020-01-07 JP JP2020000928A patent/JP6970217B2/ja not_active Expired - Fee Related
- 2020-03-17 US US16/820,886 patent/US20200253980A1/en not_active Abandoned
-
2021
- 2021-12-15 US US17/644,491 patent/US20220280523A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015529194A5 (enExample) | ||
| RU2015108755A (ru) | Комбинация ингибитора pik3 и ингибитора с-мет | |
| AU2018226470B2 (en) | Compounds for treatment of cancer | |
| AU2014372166B2 (en) | Pharmaceutical combinations | |
| AU2012328979B2 (en) | Method of treating gastrointestinal stromal tumors | |
| JP2016520131A5 (enExample) | ||
| RU2014154009A (ru) | Комбинация ингибитора 17-альфа-гидроксилазы (с17,20-лиазы) и специфического ингибитора pi-3k для лечения онкологического заболевания | |
| JP2016525076A5 (enExample) | ||
| JP2020503299A5 (enExample) | ||
| JP2014505735A5 (enExample) | ||
| RU2018104702A (ru) | Новые соединения пирролопиримидина в качестве ингибиторов протеинкиназ | |
| JP2014521725A5 (enExample) | ||
| RU2018110770A (ru) | Ингибиторы mdm2 и их комбинации | |
| JP2017528498A5 (enExample) | ||
| JP2011507854A5 (enExample) | ||
| RU2018120330A (ru) | Химерные соединения, осуществляющие нацеливание для протеолиза, и способы их получения и применения | |
| JP2011527703A (ja) | （ａ）ホスホイノシタイド３−キナーゼ阻害剤および（ｂ）Ｒａｓ／Ｒａｆ／Ｍｅｋ経路のモジュレーターの配合物 | |
| RU2015139590A (ru) | ИНГИБИРУЮЩЕЕ Trk СОЕДИНЕНИЕ | |
| JP2018515555A5 (enExample) | ||
| JP2014513110A5 (enExample) | ||
| JP2016523974A5 (enExample) | ||
| JP2014518544A5 (enExample) | ||
| JP2012526772A5 (enExample) | ||
| JP2019505594A5 (enExample) | ||
| JP2012526766A5 (enExample) |